TG Therapeutics (TGTX) Q4 results:
Revenues: $0.04M (unch).
Net loss: ($39.6M) (+26.5%); loss/share: ($0.44) (+35.3%); Quick Assets: $140.4M (+103.8%).
Key Objectives for 2020: Report
topline PFS results from the Phase 3 UNITY-CLL trial, and if successful,
target a potential NDA/BLA submission by year-end.
Complete rolling NDA submission for umbralisib in patients with previously treated MZL and FL, in H1.
Report topline results from the Phase 3 ULTIMATE I & II trials in RMS, in H2.
Previously: TG Therapeutics EPS misses by $0.02 (March 3)
https://seekingalpha.com/news/3547937-tg-therapeutics-net-loss-improves-in-q4
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.